MAIN RESULTS OBTAINED BY REGHEALTH-RI PROJECT ON:

Transcription

1 MAIN RESULTS OBTAINED BY REGHEALTH-RI PROJECT ON: Participation of regions/countries in the Societal Challenge 1 "Health, demographic change and well-being" of H2020 Synergies between Horizon 2020 (H2020) and European Structural and Investment Funds (ESIFs) Health research and innovation in EU less-performing countries and regions Joaquín Guinea 20 th October, 2016

2 BACKGROUND STATE OF THE ART OF HEALTH RESEARCH AND INNOVATION IN EU REGIONS CONTENT INDEX 1. INTRODUCTION 1.1. Importance of health R&I in Europe 1.2. The concept of health 1.3. Methodology 2. SITUATION OF HEALTH RESEARCH & INNOVATION IN EUROPE 2.1. Research & Innovation in EU Countries R&I Inputs R&I Actors and Activities R&I Outputs Performance in EU Research Framework Programmes Innovation Component 2.2. Research & Innovation in EU Regions R&I Actors and Activities R&I Outputs Performance in EU Research Framework Programmes Innovation Component 3. ANALYSIS OF HEALTH RESEARCH & INNOVATION IN EUROPE 3.1. Detection of common patterns and analysis of key variables on Health R&I within the less performing EU regions 3.2. Determinants of Health publishing propensity at the EU regional level 3.3. A proposal for a Composite Indicator of Health Research Excellence 4. CONCLUSIONS AND POLICY RECOMMENDATIONS 5. BIBLIOGRAPHIC REFERENCES 6. ANNEXES

3 BACKGROUND: Results of calls of the "Health, demographic change and wellbeing"* of H2020 Soc. Challenge 1 [SME instrument (PHC ) not included] * Health, demographic change and wellbeing Source: European Union OpenData Portal CORDIS - EU research projects under Horizon 2020 ( ) Modified Date:

4 BACKGROUND: Survey responses from 60 Institutions from 20 European countries (Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Macedonia, Malta, Netherlands, Portugal, Romania, Slovenia, Spain, Sweden and UK) and from 4 European organizations (EUREGHA, EFPIA, COST and EC). Institution Type Regional/National/EU Agencies & Funding Institutions: 33 (55 %) Public Research Organizations: 18 (30%) Industry & Business Sector: 9 (15 %)

5 Most significant and influential factors hindering the participation of EU lessperforming regions/countries in the Societal Challenge 1 "Health, demographic change and well-being" of Horizon 2020 (H2020) Extremely populated scientific field generating a high competition to get funding Discouragement coming from low success rate Lack of expertise to prepare consistent proposals Large and complex topics more suited for the participation of reputed organizations from elite EU regions Lack of specific support to prepare the proposals Low expected reward in relation to the effort for preparing and implementing the projects/proposals

6 Potential actions for increasing the participation of less-performing regions/countries in the Societal Challenge 1 "Health, demographic change and well-being" of H2020 Design suitable actions/programmes (similar to Widening) specifically requiring the participation of less-performing regions Promote networking activities with elite institutions of EU leading regions Provide alternative funding for high quality proposals presented in H2020 that have not been successful Providing guidance and support by means of consultancy or any other services facilitating the elaboration of competitive proposals Foster mobility of researchers to excellent institutions in EU less-performing regions Design of more specific and suitable topics more accessible to less-performing regions Rewarding research teams working on H2020 with quality proposals not being funded by means of bonuses or awards Change/improve the methodology of evaluation of the proposals Allow (by the EC financial rules) the personal costs calculation in RIA, etc., in the similar way to MSCA

7 Features identified as more important and influential in hindering synergies between Horizon 2020 and European Structural and Investment Funds (ESIFs) The very high difficulty in obtaining H2020 funding from EU less performing regions institutions (Public Research Centres, Universities, Hospitals, Industry, etc.) is probably the main trouble for reaching such synergies. It seems obvious that without H2020 funding there is not possibility of synergies Significant conceptual and strategic differences between H2020 (excellent research) and ESIF (regional capacity building and overcome structural difference) make those synergies also difficult to achieve There are also important organizational and administrative differences between H2020 and ESIF in terms of timing, different cost definitions and financial management rules, etc., which makes synergies a rather complicated business

8 Available data from 194 EU Regions (18/10/2016) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) Total ESIF Research & Innovation per capita per year (planned R&I-related investments under ESIF ) Regions&countries that have selected public health & security as priority for their innovation strategies for smart specialization (RIS3)

9 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 1 Podlaskie PL 0,00 63,01 0,0% Yes 2 Lubuskie PL 0,00 52,18 0,0% Yes 3 Opolskie PL 0,00 50,86 0,0% Yes 4 Ciudad Autonoma De Melilla ES 0,00 18,30 0,0%? 5 Ciudad Autonoma De Ceuta ES 0,00 15,34 0,0%? 6 Severozapaden BG 0,00 13,05 0,0% Yes 7 Åland FI 0,00 7,15 0,0% Yes 8 Swietokrzyskie PL 0,00 65,15 0,0% Yes 9 Yugoiztochen BG 0,01 12,83 0,0% Yes 10 Podkarpackie PL 0,01 65,41 0,0% Yes 11 Severen Tsentralen BG 0,02 12,95 0,2% Yes 12 Kujawsko-Pomorskie PL 0,04 49,20 0,1% Yes 13 Sud-Vest Oltenia RO 0,04 7,57 0,6% Yes 14 Extremadura ES 0,08 37,85 0,2% No 15 Sud - Muntenia RO 0,08 7,56 1,1% Yes 16 Zapadne Slovensko SK 0,11 54,83 0,2% No 17 Zachodniopomorskie PL 0,12 49,39 0,3% Yes 18 Nord-Vest RO 0,12 7,47 1,6% Yes 19 Severozapad CZ 0,12 44,84 0,3% Yes 20 Vychodne Slovensko SK 0,14 54,21 0,3% No 21 Centru RO 0,15 7,78 1,8% Yes 22 Regiao Autonoma Dos Acores PT 0,17 121,27 0,1% Yes 23 Burgenland AT 0,19 7,78 2,4% Yes 24 Vest RO 0,20 7,39 2,6% Yes 25 Stredni Cechy CZ 0,20 43,95 0,5% Yes 26 Eszak-Magyarorszag HU 0,21 49,65 0,4% Yes 27 Del-Alfold HU 0,22 49,38 0,4% Yes 28 Slaskie PL 0,24 49,16 0,5% Yes 29 Limousin FR 0,25 10,28 2,4% Yes 30 Yuzhen Tsentralen BG 0,27 13,19 2,0% Yes

10 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 31 Champagne-Ardenne FR 0,28 8,27 3,3% No 32 Nyugat-Dunantul HU 0,28 49,27 0,6% Yes 33 Severoiztochen BG 0,28 12,82 2,2% Yes 34 Sud-Est RO 0,28 7,44 3,7% Yes 35 Kozep-Dunantul HU 0,29 49,28 0,6% Yes 36 Stredni Morava CZ 0,32 44,74 0,7% Yes 37 Stredne Slovensko SK 0,34 54,49 0,6% No 38 Valle daosta IT 0,35 11,29 3,0% No 39 Notio Aigaio EL 0,37 11,32 3,2% No 40 Corse FR 0,39 10,14 3,7% No 41 Lodzkie PL 0,41 57,41 0,7% Yes 42 Eszak-Alfold HU 0,42 49,20 0,8% Yes 43 Warminsko-Mazurskie PL 0,43 72,11 0,6% Yes 44 Nord-Est RO 0,44 7,83 5,3% Yes 45 Calabria IT 0,45 24,86 1,8% Yes 46 Jihozapad CZ 0,46 44,87 1,0% Yes 47 Molise IT 0,48 11,51 4,0% Yes 48 Del-Dunantul HU 0,53 49,69 1,1% Yes 49 Poitou-Charentes FR 0,58 5,79 9,1% Yes 50 Abruzzo IT 0,62 9,08 6,4% Yes 51 Islas Baleares ES 0,65 7,95 7,6% Yes 52 Smaland och oarna SE 0,69 8,78 7,3% Yes 53 Haute-Normandie FR 0,70 10,27 6,4% Yes 54 Basse-Normandie FR 0,74 7,89 8,5% Yes 55 Lubelskie PL 0,76 59,84 1,3% Yes 56 Moravskoslezsko CZ 0,76 44,86 1,7% Yes 57 Sicilia IT 0,77 25,75 2,9% No 58 Dolnoslaskie PL 0,79 45,26 1,7% Yes 59 Lietuva LT 0,82 48,61 1,7% Yes 60 Severovychod CZ 0,91 44,56 2,0% Yes

11 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 61 Pomorskie PL 0,91 48,55 1,8% Yes 62 Puglia IT 0,93 26,65 3,4% Yes 63 Picardie FR 0,93 8,05 10,4% Yes 64 Bourgogne FR 0,95 4,99 16,0% Yes 65 Lorraine FR 0,96 4,10 19,0% Yes 66 Sachsen-Anhalt DE 1,04 27,88 3,6% Yes 67 Wielkopolskie PL 1,04 50,16 2,0% Yes 68 Regiao Autonoma Da Madeira PT 1,05 30,58 3,3% Yes 69 Franche-Comte FR 1,16 10,05 10,3% No 70 Centre FR 1,19 4,02 22,8% No 71 Castilla-La Mancha ES 1,24 24,19 4,9% Yes 72 Campania IT 1,30 23,90 5,2% Yes 73 Alentejo PT 1,44 94,68 1,5% Yes 74 Hrvatska HR 1,45 28,56 4,8% Yes 75 Basilicata IT 1,45 30,95 4,5% No 76 Marche IT 1,45 6,92 17,3% Yes 77 Malopolskie PL 1,48 51,39 2,8% Yes 78 Nord - Pas-De-Calais FR 1,49 6,51 18,6% Yes 79 Voreio Aigaio EL 1,60 29,95 5,1% No 80 Canarias ES 1,65 22,63 6,8% Yes 81 Principado de Asturias ES 1,73 15,64 10,0% Yes 82 Sjaelland DK 1,84 7,52 19,7% Yes 83 La Rioja ES 1,89 15,99 10,6% No 84 Bolzano IT 1,90 5,18 26,8% Yes 85 Andalucia ES 1,90 26,19 6,8% Yes 86 Yugozapaden BG 1,91 13,09 12,7% Yes 87 Auvergne FR 1,93 7,13 21,3% Yes 88 Vorarlberg AT 1,96 4,34 31,1% Yes 89 Pays De La Loire FR 2,02 5,60 26,5% Yes 90 Region De Murcia ES 2,02 25,22 7,4% Yes

12 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 91 Umbria IT 2,13 10,87 16,4% No 92 Latvija LV 2,21 47,99 4,4% No 93 Mazowieckie PL 2,23 31,28 6,7% Yes 94 Saarland DE 2,29,16 24,2% Yes 95 Schleswig-Holstein DE 2,39 8,60 21,7% Yes 96 Veneto IT 2,41 4,25 36,2% No 97 Mecklenburg-Vorpommern DE 2,52 25,72 8,9% Yes 98 Wales UK 2,68 24,61 9,8% Yes 99 Algarve PT 2,73 28,49 8,8% Yes 100 Brandenburg DE 2,76 26,20 9,5% Yes 101 Jihovychod CZ 2,81 44,82 5,9% Yes 102 North West (England) UK 2,85 2,65 51,8% Yes 103 Rheinland-Pfalz DE 2,86 3,62 44,1% Yes 104 Galicia ES 2,88 17,64 14,0% Yes 105 Aquitaine FR 2,91 8,99 24,5% No 106 Languedoc-Roussillon FR 2,97 6,15 32,6% No 107 Thuringen DE 3,00 26,79 10,1% Yes 108 Castilla Y Leon ES 3,00 13,99 17,7% Yes 109 Malta MT 3,00 26,29 10,3% Yes 110 Etela-Suomi FI 3,04 12,71 19,3% No 111 Bretagne FR 3,06 4,22 42,0% Yes 112 Friuli-Venezia Giulia IT 3,08 9,64 24,2% No 113 Niedersachsen DE 3,34 4,77 41,1% Yes 114 Sardegna IT 3,35 15,07 18,2% Yes 115Norra Mellansverige SE 3,39 16,18 17,3% Yes 116 Norte PT 3,70 73,15 4,8% Yes 117 Northern Ireland UK 3,76 17,23 17,9% Yes 118 Centro PT 3,89 62,85 5,8% Yes 119Provence-Alpes-Côte Dazur FR 3,91 3,42 53,3% Yes 120 Hessen DE 3,93 2,71 59,2% Yes

13 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 121 Bucuresti - Ilfov RO 4,05 12,63 24,3% Yes 122 Comunidad Valenciana ES 4,10 13,37 23,5% Yes 123 Tirol AT 4,23 4,70 47,4% Yes 124 Pohjois- Ja Ita-Suomi FI 4,27 13,69 23,7% No 125 Midi-Pyrenees FR 4,35 3,42 56,0% Yes 126 Cantabria ES 4,36 10,32 29,7% Yes 127East Midlands (England) UK 4,39 4,79 47,8% Yes 128 Niederosterreich AT 4,39 4,86 47,4% Yes 129 West Midlands (England) UK 4,43 2,53 63,7% Yes 130 Emilia-Romagna IT 4,59 2,98 60,7% Yes 131 Syddanmark DK 4,64 4,95 48,4% Yes 132 Kozep-Magyarorszag HU 4,69 4,92 48,8% Yes 133 Region Wallonne BE 4,71 9,06 34,2% Yes 134 North East (England) UK 4,94 2,60 65,5% Yes 135Bratislavsky Kraj SK 5,11 37,57 12,0% Yes 136 Lombardia IT 5,13 3,50 59,5% Yes 137 Oberosterreich AT 5,13 4,52 53,2% Yes 138 Yorkshire and The Humber UK 5,35 2,60 67,3% Yes 139 Alsace FR 5,50 2,97 64,9% No 140 Nordrhein-Westfalen DE 5,74 5,75 50,0% Yes 141 Lansi-Suomi FI 5,76 13,38 30,1% No 142 Rhone-Alpes FR 5,82 3,90 59,9% Yes 143Mellersta Norrland SE 6,39 24,09 21,0% Yes 144 Aragon ES 6,42 8,50 43,0% No 145 Karnten AT 6,48 5,10 56,0% Yes 146 Piemonte IT 6,56 6,71 49,5% Yes 147 Salzburg AT 6,73 4,73 58,7% Yes 148 Sachsen DE 6,87 29,98 18,6% Yes 149 Toscana IT 7,09 6,54 52,0% No 150 Hamburg DE 7,22 2,54 73,9% Yes

14 EU Regions ordered by H2020 funding (increasing order) Total H2020 per capita per year (allocated funding 2014-March 2016 to all type of actions&thematic areas) vs Total ESIF Research & Innovation per capita per year (planned R&I-related % H2020 Health as RIS3 priority investments under ESIF ) 161 Noord-Nederland NL 9,05 8,63 51,2% Yes 162 Eesti EE 9,05 100,71 8,2% Yes 163 Scotland UK 9,30 7,02 57,0% Yes 164 Nordjylland DK 9,33 4,51 67,4% Yes 165 Lisboa PT 9,77 15,13 39,2% Yes 166 Vastsverige SE 10,33 5,66 64,6% Yes 167 Cataluna ES 10,42 13,29 44,0% Yes 168 Vlaams Gewest BE 10,86 3,82 74,0% Yes 169 Sydsverige SE 11,13 4,53 71,1% Yes 170 Attiki EL 11,29 9,08 55,4% No 171 Zuid-Nederland NL 11,41 5,46 67,6% Yes 172 Comunidad De Madrid ES 11,49 8,58 57,2% Yes 173 Östra Mellansverige SE 11,59 4,53 71,9% Yes 174 Bayern DE 11,79 2,42 82,9% Yes 175 Midtjylland DK 11,90 4,50 72,6% Yes 176 Berlin DE 12,11 15,43 44,0% Yes 177 Oost-Nederland NL 12,19 5,90 67,4% Yes 178 London UK 12,80 4,68 73,2% Yes 179 Kypros CY 13,68 12,77 51,7% Yes 180 Kriti EL 14,04 16,24 46,4% No 181 Southern and Eastern IE 15,24 4,81 76,0% Yes 182 Trento IT 16,01 11,08 59,1% Yes 183 Ile De France FR 16,36 1,09 93,7% Yes 184 Pais Vasco ES 16,80 12,34 57,7% Yes 185 Luxembourg LU 18,07 2,89 86,2% Yes 186 West-Nederland NL 18,49 2,57 87,8% Yes 187 Stockholm SE 19,35 2,66 87,9% Yes 188 Steiermark AT 20,66 4,82 81,1% Yes 189 Övre Norrland SE 20,95 34,03 38,1% Yes 190 Bremen DE 20,97 13,01 61,7% Yes 191 Wien AT 22,70 4,79 82,6% Yes 192 Hovedstaden DK 28,25 4,53 86,2% Yes 193 Helsinki-Uusimaa FI 32,46 12,49 72,2% Yes 194 Region De Bruxelles-Capitale BE 37,97 4,85 88,7% Yes

15 Potential actions for improving the synergies between Horizon 2020 and European Structural and Investment Funds (ESIFs) Design appropriate (i.e. more flexible) bureaucratic and administrative procedures of ESIFs funding in order to facilitate synergies and complementary use of various funding sources Provide appropriate information and support on synergies to those institutions interested to participate in H2020 and/or ESIFs Coordinate the timing of calls of the regional programmes with those of H2020 Align the regional research and innovation policy with the H2020 Increase the number of H2020 topics/actions/areas/etc. specifically designed to promote and/or facilitate synergies between H2020 and ESIFs Training and incentives to policy makers, managing authorities and intermediary bodies at member state level Force the Seal of Excellence tool to national governments via ESIF for appropriate programmes

16 Key issues identified as the main negative factors hindering health research and innovation progress of in EU less-performing countries/regions Brain drain in the field of health research in a region/country Low understanding of specific research and innovation issues by policy and decision makers Insufficient knowledge transfer from public research organizations to interested stakeholders Poor investment in public research and, above all, in private research Insufficient linkages with excellent organizations, companies, etc., from advanced and leading European regions and countries (international collaboration)

17 Potential actions for improving the health research and innovation situation in EU less-performing countries and regions Promote collaborative actions between leading and less-performing European regions Design research programmes aimed at fostering the stay/return of researchers in the region/country Improve the alignment or interlink between innovation and research policy Compile better data on innovation both at national and regional level Increase the resources for specific research and innovation instruments Analyze private sector and society needs/concerns in order to be fitted to research and innovation activities in public sector (PROs and universities) Elaborate clear and easy-to-understand materials (guides, policy briefs,...) and implement training activities for policy and decision makers in order to support and facilitate a better understanding of research and innovation processes Study the Brain Drain phenomenon in-depth Help with long-term basic national problems like salary limits in some low performing countries

18 FINAL KEY MESSAGES/RECOMMENDATIONS TO DG RESEARCH&INNOVATION: ALLOCATE A MINIMUM OF 5% OF THE H2020 HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING BUDGET SPECIFICALLY TO LESS PERFORMING EUROPEAN REGIONS/COUNTRIES TO REDUCE THE INCREASING GAP IN HEALTH RESEARCH AND INNOVATION IN EU TO DG REGIO: DESIGN APPROPRIATE (I.E. MORE FLEXIBLE) BUREAUCRATIC AND ADMINISTRATIVE PROCEDURES OF ESIFs FUNDING IN ORDER TO FACILITATE THE SYNERGIES AND COMPLEMENTARY USE OF DIFFERENT FUNDING SOURCES TO REGIONAL/NATIONAL HEALTH RESEARCH&INNOVATION AUTHORITIES: IMPROVE THE ALIGNMENT AND INTERLINK BETWEEN HEALTH RESEARCH AND HEALTH INNOVATION POLICIES DESIGN RESEARCH AND INNOVATION PROGRAMMES AIMED AT FOSTERING THE STAY/RETURN OF RESEARCHERS IN THE REGION/COUNTRY

19 INNOVATEC (Spain) European Regional and Local Health Authorities (EUREGHA) (EU) University of Trieste (Italy) Association of Research Based Pharmaceutical Manufacturers (ARPharM) (Bulgaria) Health ClusterNET (Netherlands) Libertas International University (Croatia) Polish Academy of Sciences /Nencki Institute (Poland) Ministry of Finance and Public Administration (Spain) University of Tartu (Estonia) Academy of Sciences of the Czech Republic (Czech Republic) Agencia de Innovación, Financiación e Internacionalización Empresarial de Castilla y León (Spain) Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC), (Spain) Agency for Healthcare Quality & Assessment of Catalonia (Spain) Portuguese National Innovation Agency (ANI) (Portugal) Bayer AG/ European Federation of Pharmaceutical Industries and Associations (EFPIA) (Germany / EU) Comission for Coordination and Regional Dev. of the Algarve) (Portugal) Consejería Igualdad, Salud y Políticas Sociales- Junta de Andalucía (Spain) Democritus University of Thrace (Greece) Department of Health Care, region Västra Götaland (Sweden) Department of Informatics Ionian University Corfu (Greece) Digital Health Institute, Scotland (UK) EIT Health KIC (Hungary) Estonian Research Council (Estonia) Eurasante / NHL Cluster (France) European Commission - DG Research&Innov. (EU) European Commission - DG CONNECT (EU) European Commission - IPTS (EU) Spanish Ministry of Economy and Competitiveness (Spain) / COST (EU) Fundación Publica Andaluza Progreso y Salud (Spain) Health Institute 'Carlos III' (ISCIII), (Spain) Inkubator D.o.o. Sežana (Slovenia) Inst. Podstawowych Problemów Techniki Polskiej Akademii Nauk. (Poland) Italian Ministry of Health (Italy) Junta de Castilla y León (Spain) Klaster LifeScience Krakow (Poland) Logotech SA (Greece) London School of Hygiene and Trop. Medicine (UK) Macedonian Academy of Sciences and Arts, Research Centre "Georgi D. Efremov" (Macedonia) Marche Region, Industrial Research and Innovation Office (Italy) Marshal Office of Świętokrzyskie Region (Poland) Marshal Office of the Lubelskie Voivodeship (Poland) MidTECH Innovations (UK) Ministry of Science, Education and Sports (Croatia) National Authority for Scientific Research and Innovation (Romania) National Documentation Centre (Greece) North East Regional Development Agency (Romania) Ovidius University Constanta (Romania) Riga Stradins University (Latvia) South Moravian Center for International Mobility, Brno, Czech Republic (Czech Republic) South Transdanubian Regional Development Agency (Hungary) St. Anne's University Hospital in Brno-Int. Clinical Research Center (Czech Republic) State Education Development Agency (Latvia) Technology Centre of the Czech Academy of Sciences (Czech Republic) The Innovative Pharmaceutical Industry Association (Lithuania) University of Algarve (Portugal) University of Malta (Malta) University of Nova Gorica (Slovenia ) University of Pécs (Hungary) Upper Silesian Agency for Entrepreneurship and Development Ltd. (Poland)